查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1701346

Keytruda 市場規模、佔有率、趨勢分析報告：按應用程式、付款人、分銷管道、地區、細分市場預測，2025 年至 2030 年

Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Keytruda 市場成長與趨勢

根據Grand View Research, Inc.的最新報告，預計到2030年全球Keytruda市場規模將達到266.3億美元，2025年至2030年期間的複合年成長率為-3.23%。

市場的成長軌跡正在略微放緩。然而，聯合治療與化療、標靶藥物和其他免疫療法聯合使用可以改善療效，從而推動市場向前發展。正在進行的臨床試驗正在評估其在其他癌症適應症中的療效，特別是生物標記主導的治療方法。該藥物能夠延長三陰性乳癌、肺癌和尿路上皮癌等高難度癌症的無惡化生存期，進一步提升了在市場上的地位。此外，監管活動不斷增加，評估 Keytruda 在早期癌症中的價值，加速其在新輔助和輔助治療中的應用。

儘管Keytruda擁有強大的市場地位，但它也面臨挑戰，主要是因為專利到期。生物相似藥競爭的引入預計會帶來定價壓力並降低市場獨佔性。為了解決這個問題，默克公司正在積極推行生命週期管理策略，包括開發更容易管理的皮下製劑作為靜脈注射的替代品。最近的 3 期臨床試驗已證實，Keytruda 的 SC 製劑保持了相當的功效和安全性，有可能擴大其商業性可用性。

競爭格局也在不斷演變， Opdivo和TECENTRIQ等 PD-1/PD-L1 抑制劑正在爭奪市場佔有率。此外，下一代免疫療法和新治療方法可能會威脅 Keytruda 的優勢。不過，默克對研發和策略合作的持續投入預計將有助於Keytruda保持在腫瘤領域的地位。對於默克公司而言，我們不斷努力擴大適應症，探索新的組合方案，並透過創新配方提高患者的便利性，對於維持我們在免疫腫瘤市場的領先地位至關重要。

Keytruda 面臨的最大挑戰之一是其專利到期，這將為生物相似藥市場帶來競爭。因此，多家製藥公司正在積極開發生物相似藥，這可能對默克公司Keytruda的企業收益產生重大影響。隨著市場獨佔權的喪失，我們預計將面臨更大的定價壓力和報銷挑戰，特別是在成本敏感的市場。此外，圍繞生物相似藥核准的監管障礙和訴訟可能會造成市場不確定性。為了降低這些風險，默克專注於生命週期管理策略，例如開發新配方和擴大適應症，以便在生物相似藥進入市場後仍能維持需求。

同時，Keytruda 仍然是一個巨大的商機，特別是在聯合治療和早期治療領域。隨著 Keytruda 繼續證明對具有某些基因和分子標記的患者有效，向個人化醫療和生物標記主導的癌症治療的轉變代表著一個主要的成長途徑。研究 KEYTRUDA 與新型藥物（如抗體藥物複合體和下一代免疫查核點抑制劑）聯合治療的臨床試驗可能會進一步增強 KEYTRUDA 的治療潛力。此外，新輔助和輔助治療的核准將延長治療時間，擴大目標患者群體並推動持續的需求。

默克公司的另一個關鍵機會在於開發 Keytruda 的皮下（SC）製劑，旨在提高患者的便利性和可及性。如果核准，這種製劑可以為面臨靜脈注射障礙（例如難以進入輸液中心）的患者提供一種替代方案。此外，SC 配方可以透過提供差異化產品來延緩生物相似藥的影響，有助於延長 Keytruda 的市場獨佔權。此外，亞太和拉丁美洲新興的腫瘤市場為市場擴張提供了機會，因為癌症發生率的上升和醫療保健基礎設施的改善將推動對先進免疫療法的需求。透過對新適應症、組合方案和創新藥物傳遞方法的策略性投資，默克致力於讓 KEYTRUDA 在全球免疫腫瘤市場保持強勢地位，儘管未來面臨挑戰。

Keytruda 市場報告重點

  • 根據應用，肺癌在 2024 年佔據 Keytruda 市場的主導地位，收入佔有率最高，為 27.4%，這得益於其廣泛用於非小細胞肺癌 (NSCLC) 和小細胞肺癌 (SCLC) 的一線治療。另一方面，由於 Keytruda 在三陰性乳癌(TNBC) 中的出現以及正在進行的臨床試驗以探索其在其他乳癌亞型中的療效，預計乳癌在預測期內將以最快的複合年成長率成長。
  • 根據付款人，商業/私人保險部分在 2024 年佔據最大佔有率，為 91.0%，這得益於新興市場對免疫腫瘤療法的強大報銷支持。然而，隨著政府醫療保健計劃和國家報銷政策擴大昂貴癌症治療的覆蓋範圍，公共保險業預計將實現穩步成長。
  • 根據分銷管道，到 2024 年，醫院藥房將成為主導市場，佔有 51.8% 的佔有率，由於癌症治療中心需要管理管理和專家監督，因此佔據最高的銷售佔有率。然而，由於越來越多人轉向門診免疫療法，以及 Keytruda 皮下製劑可能獲得批准，核准專科藥房在預測期內的複合年成長率將最快，這將提高傳統醫院環境以外的可及性。
  • 2025年2月，美國食品藥物管理局（FDA）對默克公司的生技藥品申請（sBLA）授予優先審查權，該申請將Keytruda（ Pembrolizumab ）與標準治療相結合，作為可切除的局部晚期頭頸部鱗狀核准癌（LA-HNSCC）患者的手術全期治療。該決定基於 3 期 KEYNOTE-689 試驗，該試驗顯示，與單獨接受標準治療相比，接受 KEYTRUDA 方案治療的患者的無事件生存期 (EFS) 和主要病理反應 (mPR) 有統計學上顯著改善。 FDA 已將申請的目標行動日期設定為 2025 年 6 月 23 日。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章 Keytruda 市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 專利到期分析
    • 定價和報銷方案
    • 併購與交易
    • 學名藥/生物相似藥的影響

第4章 Keytruda 市場：按應用進行的業務分析

  • 2024 年和 2030 年應用市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2018-2030 年）
  • 肺癌
  • 乳癌
  • 何傑金氏淋巴瘤
  • 頭頸癌
  • 胃癌
  • 尿路上皮癌
  • 其他

5. KEYTRUDA 市場：付款人業務分析

  • 2024 年及 2030 年付款人市場佔有率
  • 付款人細分儀表板
  • 2018 年至 2030 年按付款方分類的市場規模、預測與趨勢分析
  • 商業/個人
  • 公共

第6章：Keytruda 市場：按分銷管道進行的業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 專業藥房

第7章 Keytruda 市場：區域評估與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭格局

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/列表
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc. &Sanofi SA
    • Pfizer Inc. &Seagen Inc.
    • Amgen Inc.
    • Samsung Bioepis Co., Ltd.
    • Bio-Thera Solutions, Ltd.
Product Code: GVR-4-68040-539-2

Keytruda Market Growth & Trends:

The global Keytruda market size is anticipated to reach USD 26.63 billion by 2030 and is projected to decline at a CAGR of -3.23% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing a slight decline in the growth trajectory. However, the market is moving ahead due to its effectiveness in combination therapies, enhancing outcomes when used alongside chemotherapy, targeted agents, and other immunotherapies. Ongoing clinical trials are evaluating its efficacy in additional cancer indications, particularly in biomarker-driven treatment approaches. The drug's ability to extend progression-free survival in challenging cancers such as triple-negative breast cancer, lung cancer, and urothelial carcinoma further strengthens its market presence. Additionally, regulatory bodies are increasingly recognizing the value of Keytruda in early-stage cancers, fueling its adoption in neoadjuvant and adjuvant settings.

Despite its strong market foothold, Keytruda faces challenges, primarily due to its upcoming patent expiration in 2028. The introduction of biosimilar competition is expected to create pricing pressures and reduce market exclusivity. To counter this, Merck is actively working on lifecycle management strategies, including the development of a subcutaneous (SC) formulation that offers a more convenient alternative to the intravenous (IV) version. Recent Phase 3 trials have confirmed that SC Keytruda maintains comparable efficacy and safety, potentially extending its commercial viability.

The competitive landscape is also evolving, with rival PD-1/PD-L1 inhibitors, such as Opdivo and Tecentriq, vying for market share. Additionally, next-generation immunotherapies and novel treatment modalities pose potential threats to Keytruda's dominance. However, Merck's ongoing investments in research and development, coupled with strategic collaborations, are expected to sustain Keytruda's relevance in the oncology space. The company's continued efforts to expand indications, explore new combination regimens, and enhance patient accessibility through innovative drug formulations will be crucial in maintaining its leadership in the immuno-oncology market.

One of the biggest challenges Keytruda faces is its impending patent expiration in 2028, which will open the market to biosimilar competition. As a result, several pharmaceutical companies are actively developing biosimilar versions, which could significantly impact Merck's revenue from Keytruda. With the loss of exclusivity, pricing pressures and reimbursement challenges are expected to intensify, particularly in cost-sensitive markets. Additionally, regulatory hurdles and litigation over biosimilar approvals could create market uncertainties. To mitigate these risks, Merck is focusing on life cycle management strategies, including the development of new formulations and expanded indications to sustain demand even after biosimilar entry.

At the same time, opportunities remain strong for Keytruda, particularly in combination therapies and earlier treatment lines. The shift toward personalized medicine and biomarker-driven oncology treatments presents a significant growth avenue, as Keytruda continues to demonstrate efficacy in patients with specific genetic and molecular markers. Clinical trials exploring Keytruda in combination with novel agents, such as antibody-drug conjugates and next-generation immune checkpoint inhibitors, could further enhance its therapeutic potential. Moreover, approvals in neoadjuvant and adjuvant settings are expected to increase treatment durations and expand the eligible patient pool, ensuring continued demand.

Another key opportunity for Merck lies in the development of the subcutaneous (SC) formulation of Keytruda, which aims to improve patient convenience and access. If approved, this version could offer an alternative for patients who face barriers to IV administration, such as limited access to infusion centers. The SC formulation could also help extend Keytruda's market exclusivity by offering a differentiated product that may delay the impact of biosimilars. Additionally, emerging oncology markets in Asia-Pacific and Latin America present expansion opportunities, as rising cancer prevalence and improving healthcare infrastructure drive demand for advanced immunotherapies. With strategic investments in new indications, combination regimens, and innovative drug delivery methods, Merck is positioning Keytruda to maintain its strong presence in the global immuno-oncology market, despite the challenges ahead.

Keytruda Market Report Highlights:

  • Based on application, lung cancer dominated the Keytruda market in 2024 with the largest revenue share of 27.4%, due to its widespread adoption as a first-line treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Meanwhile, breast cancer is projected to grow at the fastest CAGR over the forecast period, driven by Keytruda's increasing use in triple-negative breast cancer (TNBC) and ongoing clinical trials exploring its efficacy in other breast cancer subtypes.
  • Based on payer, the commercial/private insurance segment held the largest share of 91.0% in 2024, owing to strong reimbursement support for immuno-oncology therapies in developed markets. However, the public insurance segment is expected to see steady growth as government healthcare programs and national reimbursement policies expand access to costly cancer treatments.
  • Based on distribution channel, hospital pharmacies emerged as the dominant segment with a share of 51.8% in 2024, accounting for the highest revenue share due to the need for controlled administration and specialist supervision in oncology treatment centers. Meanwhile, specialty pharmacies are projected to witness the fastest CAGR over the forecast period, driven by the growing shift towards outpatient immunotherapy administration and potential approval of the subcutaneous Keytruda formulation, which could improve accessibility outside traditional hospital settings.
  • In February 2025, the U.S. Food and Drug Administration (FDA) granted Priority Review to Merck's supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab) in combination with standard care as a perioperative treatment for patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This decision is based on the Phase 3 KEYNOTE-689 trial, which demonstrated a statistically significant improvement in event-free survival (EFS) and major pathological response (mPR) for patients receiving the Keytruda regimen compared to standard treatment alone. The FDA has set a target action date of June 23, 2025, for this application.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Payer
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Keytruda Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Patent Expiry Analysis
    • 3.3.4. Pricing and Reimbursement Scenario
    • 3.3.5. M&A and Deals
    • 3.3.6. Impact of Generics/Biosimilars

Chapter 4. Keytruda Market: Application Business Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Lung Cancer
    • 4.4.1. Lung Cancer Market, 2018 - 2030 (USD Million)
  • 4.5. Breast Cancer
    • 4.5.1. Breast Cancer Market, 2018 - 2030 (USD Million)
  • 4.6. Hodgkin Lymphoma
    • 4.6.1. Hodgkin Lymphoma Market, 2018 - 2030 (USD Million)
  • 4.7. Head and Neck Cancer
    • 4.7.1. Head and Neck Cancer Market, 2018 - 2030 (USD Million)
  • 4.8. Gastric Cancer
    • 4.8.1. Gastric Cancer Market, 2018 - 2030 (USD Million)
  • 4.9. Urothelial Cancer
    • 4.9.1. Urothelial Cancer Market, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Keytruda Market: Payer Business Analysis

  • 5.1. Payer Market Share, 2024 & 2030
  • 5.2. Payer Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Payer, 2018 to 2030 (USD Million)
  • 5.4. Commercial/Private
    • 5.4.1. Commercial/Private Market, 2018 - 2030 (USD Million)
  • 5.5. Public
    • 5.5.1. Public Market, 2018 - 2030 (USD Million)

Chapter 6. Keytruda Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.5. Specialty Pharmacy
    • 6.5.1. Specialty Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Keytruda Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Keytruda Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Keytruda Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bristol-Myers Squibb Company
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Regeneron Pharmaceuticals, Inc. & Sanofi S.A.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc. & Seagen Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Amgen Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Samsung Bioepis Co., Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bio-Thera Solutions, Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Keytruda market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 5 Global Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 6 Global Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 7 Global Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 10 North America Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 12 North America Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16 U.S. Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 18 Canada Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 20 Canada Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 24 Mexico Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 27 Europe Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29 Europe Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 31 UK Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 33 UK Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 35 Germany Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 37 Germany Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 39 France Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 40 France Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41 France Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 43 Italy Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 45 Italy Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 47 Spain Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 49 Spain Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Norway Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 51 Norway Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 52 Norway Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 53 Norway Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Denmark Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 55 Denmark Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57 Denmark Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Sweden Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 59 Sweden Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 60 Sweden Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 61 Sweden Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia-Pacific Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia-Pacific Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 64 Asia-Pacific Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia-Pacific Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66 Asia-Pacific Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Japan Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 68 Japan Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 70 Japan Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 China Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 72 China Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 73 China Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 74 China Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 76 India Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 77 India Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 78 India Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 80 Australia Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 82 Australia Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 84 South Korea Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86 South Korea Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 88 Thailand Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 90 Thailand Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 93 Latin America Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95 Brazil Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 96 Brazil Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 97 Brazil Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 98 Brazil Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 100 Argentina Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 101 Argentina Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 102 Argentina Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa (MEA) Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 109 South Africa Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 110 South Africa Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 111 South Africa Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 117 UAE Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 118 UAE Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 119 UAE Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Keytruda market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Keytruda market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Keytruda market dynamics
  • Fig. 12 Keytruda market: Porter's five forces analysis
  • Fig. 13 Keytruda market: PESTLE analysis
  • Fig. 14 Keytruda market revenue by application, 2018 - 2030
  • Fig. 15 Lung cancer market outlook (USD Million)
  • Fig. 16 Breast cancer market growth trend (USD Million)
  • Fig. 17 Melanoma treatment market analysis (USD Million)
  • Fig. 18 Hodgkin lymphoma treatment market size (USD Million)
  • Fig. 19 Head and neck cancer Keytruda market share (USD Million)
  • Fig. 20 Gastric cancer Keytruda market revenue (USD Million)
  • Fig. 21 Urothelial cancer Keytruda market demand (USD Million)
  • Fig. 22 Other cancer applications for Keytruda (USD Million)
  • Fig. 23 Keytruda market revenue by payer type, 2018 - 2030
  • Fig. 24 Commercial/private insurance market share for Keytruda (USD Million)
  • Fig. 25 Public insurance market growth for Keytruda (USD Million)
  • Fig. 26 Keytruda market revenue by distribution channel, 2018 - 2030
  • Fig. 27 Hospital pharmacy Keytruda market analysis (USD Million)
  • Fig. 28 Specialty pharmacy Keytruda market growth trend (USD Million)
  • Fig. 29 Keytruda market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia-Pacific Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 73 Middle East & Africa (MEA) Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework